Cargando…

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)

BACKGROUND: To investigate the safety and feasibility of combining neoadjuvant sintilimab (Innovent Biologics, Suzhou, China) and chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: The study was an investigator-initiated, open-label, non-randomized, single-arm, sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhenyang, Hong, Zhi-Nuan, Xie, Shuhan, Lin, Wenwei, Lin, Yukang, Zhu, Jiafu, Yang, Xiaojie, Lin, Zhiwei, Lin, Jiangbo, Kang, Mingqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640906/ https://www.ncbi.nlm.nih.gov/pubmed/34926667 http://dx.doi.org/10.21037/atm-21-5381

Ejemplares similares

A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer
por: Zhang, Zhenyang, et al.
Publicado: (2022)

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)
por: Duan, Hongtao, et al.
Publicado: (2021)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Postoperative adjuvant therapy for resectable esophageal cancer: A protocol of a systematic review and meta-analysis
por: Chai, Tianci, et al.
Publicado: (2019)

Long intergenic non‐coding RNA Linc00485 promotes lung cancer progression by modulating miR‐298/c‐Myc axis
por: Zhang, Zhenyang, et al.
Publicado: (2020)

LGR6 is a potential diagnostic and prognostic marker for esophageal squamous cell carcinoma
por: Chai, Tianci, et al.
Publicado: (2020)

Hsa_circ_0004370 promotes esophageal cancer progression through miR-1294/LASP1 pathway
por: Zhang, Zhenyang, et al.
Publicado: (2019)

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
por: Wei, Jia, et al.
Publicado: (2023)

Comparison of high risk factors (hot food, hot beverage, alcohol, tobacco, and diet) of esophageal cancer: A protocol for a systematic review and meta-analysis
por: Chai, Tianci, et al.
Publicado: (2019)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

LncRNA C9orf139 can regulate the progression of esophageal squamous carcinoma by mediating the miR-661/HDAC11 axis
por: Yang, Xiaojie, et al.
Publicado: (2022)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Postoperative adjuvant therapy for resectable early non-small cell lung cancer: A protocol for a systematic review and meta-analysis
por: Chai, Tianci, et al.
Publicado: (2019)

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
por: Xu, Qin, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study
por: Hong, Zhi-Nuan, et al.
Publicado: (2021)

A retrospective study of the relationship between the pathologic subtype and lymph node metastasis of lung adenocarcinomas of ≤3 cm diameter
por: Lin, Wenwei, et al.
Publicado: (2020)

Application of neck anastomotic muscle flap embedded in 3-incision radical resection of oesophageal carcinoma: A protocol for systematic review and meta analysis
por: Tong, Zhangwei, et al.
Publicado: (2020)

Comparison between video-assisted thoracoscopic lung cancer resection and robot-assisted lung cancer resection: Protocol for a systematic review and meta-analysis
por: Chai, Tianci, et al.
Publicado: (2019)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
por: Liu, Linlin, et al.
Publicado: (2023)

Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Identification of potential core genes in esophageal carcinoma using bioinformatics analysis
por: Yang, Xiaojie, et al.
Publicado: (2021)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

Right versus left thoracic approach oesophagectomy for oesophageal cancer: a systematic review and meta-analysis protocol
por: Chai, Tianci, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
por: Yang, Jinsong, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
por: Han, Xiao, et al.
Publicado: (2022)

Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol
por: Huang, Wenpeng, et al.
Publicado: (2023)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
por: Fang, Xuefeng, et al.
Publicado: (2023)

Total superior vena cava reconstruction guided by preoperative three-dimensional (3D)-computed tomography bronchography and angiography
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
por: Tao, Rong, et al.
Publicado: (2021)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0inpqj4kj9k13o70rhma207nl9